Tacrine
Description
Name: Tacrine
Type: small molecule
Groups: withdrawn
Indication: For the palliative treatment of mild to moderate dementia of the Alzheimer's type.
Accession Number: DB00382 ( APRD00690)
Description: A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market.
Structure:
Prescription Products: Not Available
Generic Prescription Products: Not Available
Over the Counter Products: Not Available
International Brands
Brand Names
Brand Mixtures
Categories
Type: small molecule
Groups: withdrawn
Indication: For the palliative treatment of mild to moderate dementia of the Alzheimer's type.
Accession Number: DB00382 ( APRD00690)
Description: A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market.
Structure:
Prescription Products: Not Available
Generic Prescription Products: Not Available
Over the Counter Products: Not Available
International Brands
- No Brands
Brand Names
- No Brands
Brand Mixtures
| Brand Name | Ingredients |
|---|
| Brand Name | Ingredients |
|---|
Categories
- Nootropic Agents
- Cholinesterase Inhibitors
- Parasympathomimetics
- Acetylcholinesterase Inhibitors
- Acetylcholinesterase Inhibitors (Central)
Pharmacology
Indication: For the palliative treatment of mild to moderate dementia of the Alzheimer's type.
Pharmacodynamics: Not Available
Mechanism of action: The mechanism of tacrine is not fully known, but it is suggested that the drug is an anticholinesterase agent which reversibly binds with and inactivates cholinesterases. This inhibits the hydrolysis of acetylcholine released from functioning cholinergic neurons, thus leading to an accumulation of acetylcholine at cholinergic synapses. The result is a prolonged effect of acetylcholine.
Absorption: Tacrine is rapidly absorbed. Absolute bioavailability of tacrine is approximately 17%.
Volume of distribution:
Protein binding: 55%
Metabolism: Not Available
Route of elimination: Not Available
Half life: 2 to 4 hours
Clearance: Not Available
Toxicity: Overdosage with cholinesterase inhibitors can cause a cholinergic crisis characterized by severe nausea/vomiting, salivation, sweating, bradycardia, hypotension, collapse, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. The estimated median lethal dose of tacrine following a single oral dose in rats is 40 mg/kg, or approximately 12 times the maximum recommended human dose of 160 mg/day.
Affected organisms
SNP Mediated Adverse Drug Reactions
Pharmacodynamics: Not Available
Mechanism of action: The mechanism of tacrine is not fully known, but it is suggested that the drug is an anticholinesterase agent which reversibly binds with and inactivates cholinesterases. This inhibits the hydrolysis of acetylcholine released from functioning cholinergic neurons, thus leading to an accumulation of acetylcholine at cholinergic synapses. The result is a prolonged effect of acetylcholine.
Absorption: Tacrine is rapidly absorbed. Absolute bioavailability of tacrine is approximately 17%.
Volume of distribution:
- 349 ± 193 L
Protein binding: 55%
Metabolism: Not Available
Route of elimination: Not Available
Half life: 2 to 4 hours
Clearance: Not Available
Toxicity: Overdosage with cholinesterase inhibitors can cause a cholinergic crisis characterized by severe nausea/vomiting, salivation, sweating, bradycardia, hypotension, collapse, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. The estimated median lethal dose of tacrine following a single oral dose in rats is 40 mg/kg, or approximately 12 times the maximum recommended human dose of 160 mg/day.
Affected organisms
- Not Available
SNP Mediated Adverse Drug Reactions
- Not Available
Pharmacoeconomics
Manufacturers:
Packagers:
Dosage forms
Prices
Patents
- Shionogi pharma inc
Packagers:
- Sciele Pharma Inc.
- West-Ward Pharmaceuticals
Dosage forms
| Form | Route | Strength |
|---|
| Form | Route | Strength |
|---|
Prices
| Unit description | Cost | Unit |
|---|---|---|
| Cognex 10 mg capsule | $3.03 | capsule |
| Cognex 20 mg capsule | $3.03 | capsule |
| Cognex 40 mg capsule | $3.03 | capsule |
| Unit description | Cost | Unit |
|---|---|---|
| Cognex 10 mg capsule | $3.03 | capsule |
| Cognex 20 mg capsule | $3.03 | capsule |
| Cognex 40 mg capsule | $3.03 | capsule |
Patents
| Country | Patent Number | Approved | Expires (estimated) |
|---|
Interactions
Drug Interactions
Food Interactions:
| Drug | Interaction |
|---|---|
| Acebutolol | Tacrine may increase the bradycardic activities of Acebutolol. |
| Aclidinium | The therapeutic efficacy of Aclidinium can be decreased when used in combination with Tacrine. |
| Amitriptyline | The therapeutic efficacy of Amitriptyline can be decreased when used in combination with Tacrine. |
| Amoxapine | The therapeutic efficacy of Amoxapine can be decreased when used in combination with Tacrine. |
| Aripiprazole | Tacrine may increase the central neurotoxic activities of Aripiprazole. |
| Asenapine | Tacrine may increase the central neurotoxic activities of Asenapine. |
| Atenolol | Tacrine may increase the bradycardic activities of Atenolol. |
| Atracurium besylate | Tacrine may decrease the neuromuscular blocking activities of Atracurium besylate. |
| Atropine | The therapeutic efficacy of Atropine can be decreased when used in combination with Tacrine. |
| Azelastine | The therapeutic efficacy of Azelastine can be decreased when used in combination with Tacrine. |
| Bendroflumethiazide | Tacrine may increase the bradycardic activities of Bendroflumethiazide. |
| Benzatropine | The therapeutic efficacy of Benzatropine can be decreased when used in combination with Tacrine. |
| Betamethasone | The risk or severity of adverse effects can be increased when Betamethasone is combined with Tacrine. |
| Betaxolol | Tacrine may increase the bradycardic activities of Betaxolol. |
| Bethanechol | The risk or severity of adverse effects can be increased when Tacrine is combined with Bethanechol. |
| Bisoprolol | Tacrine may increase the bradycardic activities of Bisoprolol. |
| Brexpiprazole | Tacrine may increase the central neurotoxic activities of Brexpiprazole. |
| Brompheniramine | The therapeutic efficacy of Brompheniramine can be decreased when used in combination with Tacrine. |
| Carbachol | The risk or severity of adverse effects can be increased when Tacrine is combined with Carbachol. |
| Carbinoxamine | The therapeutic efficacy of Carbinoxamine can be decreased when used in combination with Tacrine. |
| Carteolol | Tacrine may increase the bradycardic activities of Carteolol. |
| Carvedilol | Tacrine may increase the bradycardic activities of Carvedilol. |
| Cetirizine | The therapeutic efficacy of Cetirizine can be decreased when used in combination with Tacrine. |
| Cevimeline | The risk or severity of adverse effects can be increased when Tacrine is combined with Cevimeline. |
| Chlordiazepoxide | The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Tacrine. |
| Chlorphenamine | The therapeutic efficacy of Chlorphenamine can be decreased when used in combination with Tacrine. |
| Chlorpromazine | The therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Tacrine. |
| Cisatracurium besylate | Tacrine may decrease the neuromuscular blocking activities of Cisatracurium besylate. |
| Clemastine | The therapeutic efficacy of Clemastine can be decreased when used in combination with Tacrine. |
| Clidinium | The therapeutic efficacy of Clidinium can be decreased when used in combination with Tacrine. |
| Clofedanol | The therapeutic efficacy of Clofedanol can be decreased when used in combination with Tacrine. |
| Clomipramine | The therapeutic efficacy of Clomipramine can be decreased when used in combination with Tacrine. |
| Clozapine | The therapeutic efficacy of Clozapine can be decreased when used in combination with Tacrine. |
| Codeine | The therapeutic efficacy of Codeine can be decreased when used in combination with Tacrine. |
| Corticotropin | The risk or severity of adverse effects can be increased when Corticotropin is combined with Tacrine. |
| Cortisone acetate | The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Tacrine. |
| Cyclizine | The therapeutic efficacy of Cyclizine can be decreased when used in combination with Tacrine. |
| Cyclobenzaprine | The therapeutic efficacy of Cyclobenzaprine can be decreased when used in combination with Tacrine. |
| Cyclopentolate | The therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Tacrine. |
| Cyproheptadine | The therapeutic efficacy of Cyproheptadine can be decreased when used in combination with Tacrine. |
| Darifenacin | The therapeutic efficacy of Darifenacin can be decreased when used in combination with Tacrine. |
| Desipramine | The therapeutic efficacy of Desipramine can be decreased when used in combination with Tacrine. |
| Desloratadine | The therapeutic efficacy of Desloratadine can be decreased when used in combination with Tacrine. |
| Dexamethasone | The risk or severity of adverse effects can be increased when Dexamethasone is combined with Tacrine. |
| Dexbrompheniramine | The therapeutic efficacy of Dexbrompheniramine can be decreased when used in combination with Tacrine. |
| Dexchlorpheniramine maleate | The therapeutic efficacy of Dexchlorpheniramine maleate can be decreased when used in combination with Tacrine. |
| Dicyclomine | The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Tacrine. |
| Difenoxin | The therapeutic efficacy of Difenoxin can be decreased when used in combination with Tacrine. |
| Dimenhydrinate | The therapeutic efficacy of Dimenhydrinate can be decreased when used in combination with Tacrine. |
| Diphenhydramine | The therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Tacrine. |
| Diphenoxylate | The therapeutic efficacy of Diphenoxylate can be decreased when used in combination with Tacrine. |
| Dipyridamole | The therapeutic efficacy of Tacrine can be decreased when used in combination with Dipyridamole. |
| Disopyramide | The therapeutic efficacy of Disopyramide can be decreased when used in combination with Tacrine. |
| Doxepin | The therapeutic efficacy of Doxepin can be decreased when used in combination with Tacrine. |
| Doxylamine | The therapeutic efficacy of Doxylamine can be decreased when used in combination with Tacrine. |
| Droperidol | The therapeutic efficacy of Droperidol can be decreased when used in combination with Tacrine. |
| Esmolol | Tacrine may increase the bradycardic activities of Esmolol. |
| Fenoterol | The therapeutic efficacy of Fenoterol can be decreased when used in combination with Tacrine. |
| Fesoterodine | The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Tacrine. |
| Fexofenadine | The therapeutic efficacy of Fexofenadine can be decreased when used in combination with Tacrine. |
| Flavoxate | The therapeutic efficacy of Flavoxate can be decreased when used in combination with Tacrine. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Tacrine. |
| Flupentixol | The therapeutic efficacy of Flupentixol can be decreased when used in combination with Tacrine. |
| Fluphenazine | The therapeutic efficacy of Fluphenazine can be decreased when used in combination with Tacrine. |
| Fluticasone Propionate | The therapeutic efficacy of Fluticasone Propionate can be decreased when used in combination with Tacrine. |
| Glycopyrrolate | The therapeutic efficacy of Glycopyrrolate can be decreased when used in combination with Tacrine. |
| Guanidine | The risk or severity of adverse effects can be increased when Tacrine is combined with Guanidine. |
| Haloperidol | The therapeutic efficacy of Haloperidol can be decreased when used in combination with Tacrine. |
| Homatropine | The therapeutic efficacy of Homatropine can be decreased when used in combination with Tacrine. |
| Hydrocortisone | The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Tacrine. |
| Hydroxyzine | The therapeutic efficacy of Hydroxyzine can be decreased when used in combination with Tacrine. |
| Hyoscyamine | The therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Tacrine. |
| Iloperidone | Tacrine may increase the central neurotoxic activities of Iloperidone. |
| Imipramine | The therapeutic efficacy of Imipramine can be decreased when used in combination with Tacrine. |
| Ipratropium bromide | The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Tacrine. |
| Isocarboxazid | The therapeutic efficacy of Isocarboxazid can be decreased when used in combination with Tacrine. |
| Labetalol | Tacrine may increase the bradycardic activities of Labetalol. |
| Levocabastine | The therapeutic efficacy of Levocabastine can be decreased when used in combination with Tacrine. |
| Levocetirizine | The therapeutic efficacy of Levocetirizine can be decreased when used in combination with Tacrine. |
| Loratadine | The therapeutic efficacy of Loratadine can be decreased when used in combination with Tacrine. |
| Loxapine | The therapeutic efficacy of Loxapine can be decreased when used in combination with Tacrine. |
| Lurasidone | Tacrine may increase the central neurotoxic activities of Lurasidone. |
| Maprotiline | The therapeutic efficacy of Maprotiline can be decreased when used in combination with Tacrine. |
| Meclizine | The therapeutic efficacy of Meclizine can be decreased when used in combination with Tacrine. |
| Mepenzolate | The therapeutic efficacy of Mepenzolate can be decreased when used in combination with Tacrine. |
| Methacholine | The risk or severity of adverse effects can be increased when Tacrine is combined with Methacholine. |
| Methotrimeprazine | The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Tacrine. |
| Methscopolamine | The therapeutic efficacy of Methscopolamine can be decreased when used in combination with Tacrine. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Tacrine. |
| Metoprolol | Tacrine may increase the bradycardic activities of Metoprolol. |
| Moclobemide | The therapeutic efficacy of Moclobemide can be decreased when used in combination with Tacrine. |
| Nadolol | Tacrine may increase the bradycardic activities of Nadolol. |
| Nebivolol | Tacrine may increase the bradycardic activities of Nebivolol. |
| Nortriptyline | The therapeutic efficacy of Nortriptyline can be decreased when used in combination with Tacrine. |
| Olanzapine | The therapeutic efficacy of Olanzapine can be decreased when used in combination with Tacrine. |
| Olopatadine | The therapeutic efficacy of Olopatadine can be decreased when used in combination with Tacrine. |
| Orphenadrine | The therapeutic efficacy of Orphenadrine can be decreased when used in combination with Tacrine. |
| Oxybutynin | The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Tacrine. |
| Paliperidone | Tacrine may increase the central neurotoxic activities of Paliperidone. |
| Pancuronium | Tacrine may decrease the neuromuscular blocking activities of Pancuronium. |
| Penbutolol | Tacrine may increase the bradycardic activities of Penbutolol. |
| Perphenazine | The therapeutic efficacy of Perphenazine can be decreased when used in combination with Tacrine. |
| Phenelzine | The therapeutic efficacy of Phenelzine can be decreased when used in combination with Tacrine. |
| Pilocarpine | The risk or severity of adverse effects can be increased when Tacrine is combined with Pilocarpine. |
| Pimozide | The therapeutic efficacy of Pimozide can be decreased when used in combination with Tacrine. |
| Pindolol | Tacrine may increase the bradycardic activities of Pindolol. |
| Pizotifen | The therapeutic efficacy of Pizotifen can be decreased when used in combination with Tacrine. |
| Prednisolone | The risk or severity of adverse effects can be increased when Prednisolone is combined with Tacrine. |
| Prednisone | The risk or severity of adverse effects can be increased when Prednisone is combined with Tacrine. |
| Prochlorperazine | The therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Tacrine. |
| Procyclidine | The therapeutic efficacy of Procyclidine can be decreased when used in combination with Tacrine. |
| Promazine | The therapeutic efficacy of Promazine can be decreased when used in combination with Tacrine. |
| Promethazine | The therapeutic efficacy of Promethazine can be decreased when used in combination with Tacrine. |
| Propantheline | The therapeutic efficacy of Propantheline can be decreased when used in combination with Tacrine. |
| Propranolol | Tacrine may increase the bradycardic activities of Propranolol. |
| Protriptyline | The therapeutic efficacy of Protriptyline can be decreased when used in combination with Tacrine. |
| Quetiapine | The therapeutic efficacy of Quetiapine can be decreased when used in combination with Tacrine. |
| Repository corticotropin | The risk or severity of adverse effects can be increased when Repository corticotropin is combined with Tacrine. |
| Risperidone | The therapeutic efficacy of Risperidone can be decreased when used in combination with Tacrine. |
| Rocuronium | Tacrine may decrease the neuromuscular blocking activities of Rocuronium. |
| Scopolamine | The therapeutic efficacy of Scopolamine can be decreased when used in combination with Tacrine. |
| Scopolamine butylbromide | The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Tacrine. |
| Solifenacin | The therapeutic efficacy of Solifenacin can be decreased when used in combination with Tacrine. |
| Sotalol | Tacrine may increase the bradycardic activities of Sotalol. |
| Succinylcholine | The serum concentration of Succinylcholine can be increased when it is combined with Tacrine. |
| Thioridazine | The therapeutic efficacy of Thioridazine can be decreased when used in combination with Tacrine. |
| Thiothixene | The therapeutic efficacy of Thiothixene can be decreased when used in combination with Tacrine. |
| Timolol | Tacrine may increase the bradycardic activities of Timolol. |
| Tiotropium | The therapeutic efficacy of Tiotropium can be decreased when used in combination with Tacrine. |
| Tolterodine | The therapeutic efficacy of Tolterodine can be decreased when used in combination with Tacrine. |
| Tranylcypromine | The therapeutic efficacy of Tranylcypromine can be decreased when used in combination with Tacrine. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Triamcinolone is combined with Tacrine. |
| Trifluoperazine | The therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Tacrine. |
| Trihexyphenidyl | The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Tacrine. |
| Trimethobenzamide | The therapeutic efficacy of Trimethobenzamide can be decreased when used in combination with Tacrine. |
| Trimipramine | The therapeutic efficacy of Trimipramine can be decreased when used in combination with Tacrine. |
| Triprolidine | The therapeutic efficacy of Triprolidine can be decreased when used in combination with Tacrine. |
| Trospium | The therapeutic efficacy of Trospium can be decreased when used in combination with Tacrine. |
| Umeclidinium | The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Tacrine. |
| Vecuronium | Tacrine may decrease the neuromuscular blocking activities of Vecuronium. |
| Ziprasidone | Tacrine may increase the central neurotoxic activities of Ziprasidone. |
| Zuclopenthixol | The therapeutic efficacy of Zuclopenthixol can be decreased when used in combination with Tacrine. |
| Drug | Interaction |
|---|---|
| Acebutolol | Tacrine may increase the bradycardic activities of Acebutolol. |
| Aclidinium | The therapeutic efficacy of Aclidinium can be decreased when used in combination with Tacrine. |
| Amitriptyline | The therapeutic efficacy of Amitriptyline can be decreased when used in combination with Tacrine. |
| Amoxapine | The therapeutic efficacy of Amoxapine can be decreased when used in combination with Tacrine. |
| Aripiprazole | Tacrine may increase the central neurotoxic activities of Aripiprazole. |
| Asenapine | Tacrine may increase the central neurotoxic activities of Asenapine. |
| Atenolol | Tacrine may increase the bradycardic activities of Atenolol. |
| Atracurium besylate | Tacrine may decrease the neuromuscular blocking activities of Atracurium besylate. |
| Atropine | The therapeutic efficacy of Atropine can be decreased when used in combination with Tacrine. |
| Azelastine | The therapeutic efficacy of Azelastine can be decreased when used in combination with Tacrine. |
| Bendroflumethiazide | Tacrine may increase the bradycardic activities of Bendroflumethiazide. |
| Benzatropine | The therapeutic efficacy of Benzatropine can be decreased when used in combination with Tacrine. |
| Betamethasone | The risk or severity of adverse effects can be increased when Betamethasone is combined with Tacrine. |
| Betaxolol | Tacrine may increase the bradycardic activities of Betaxolol. |
| Bethanechol | The risk or severity of adverse effects can be increased when Tacrine is combined with Bethanechol. |
| Bisoprolol | Tacrine may increase the bradycardic activities of Bisoprolol. |
| Brexpiprazole | Tacrine may increase the central neurotoxic activities of Brexpiprazole. |
| Brompheniramine | The therapeutic efficacy of Brompheniramine can be decreased when used in combination with Tacrine. |
| Carbachol | The risk or severity of adverse effects can be increased when Tacrine is combined with Carbachol. |
| Carbinoxamine | The therapeutic efficacy of Carbinoxamine can be decreased when used in combination with Tacrine. |
| Carteolol | Tacrine may increase the bradycardic activities of Carteolol. |
| Carvedilol | Tacrine may increase the bradycardic activities of Carvedilol. |
| Cetirizine | The therapeutic efficacy of Cetirizine can be decreased when used in combination with Tacrine. |
| Cevimeline | The risk or severity of adverse effects can be increased when Tacrine is combined with Cevimeline. |
| Chlordiazepoxide | The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Tacrine. |
| Chlorphenamine | The therapeutic efficacy of Chlorphenamine can be decreased when used in combination with Tacrine. |
| Chlorpromazine | The therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Tacrine. |
| Cisatracurium besylate | Tacrine may decrease the neuromuscular blocking activities of Cisatracurium besylate. |
| Clemastine | The therapeutic efficacy of Clemastine can be decreased when used in combination with Tacrine. |
| Clidinium | The therapeutic efficacy of Clidinium can be decreased when used in combination with Tacrine. |
| Clofedanol | The therapeutic efficacy of Clofedanol can be decreased when used in combination with Tacrine. |
| Clomipramine | The therapeutic efficacy of Clomipramine can be decreased when used in combination with Tacrine. |
| Clozapine | The therapeutic efficacy of Clozapine can be decreased when used in combination with Tacrine. |
| Codeine | The therapeutic efficacy of Codeine can be decreased when used in combination with Tacrine. |
| Corticotropin | The risk or severity of adverse effects can be increased when Corticotropin is combined with Tacrine. |
| Cortisone acetate | The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Tacrine. |
| Cyclizine | The therapeutic efficacy of Cyclizine can be decreased when used in combination with Tacrine. |
| Cyclobenzaprine | The therapeutic efficacy of Cyclobenzaprine can be decreased when used in combination with Tacrine. |
| Cyclopentolate | The therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Tacrine. |
| Cyproheptadine | The therapeutic efficacy of Cyproheptadine can be decreased when used in combination with Tacrine. |
| Darifenacin | The therapeutic efficacy of Darifenacin can be decreased when used in combination with Tacrine. |
| Desipramine | The therapeutic efficacy of Desipramine can be decreased when used in combination with Tacrine. |
| Desloratadine | The therapeutic efficacy of Desloratadine can be decreased when used in combination with Tacrine. |
| Dexamethasone | The risk or severity of adverse effects can be increased when Dexamethasone is combined with Tacrine. |
| Dexbrompheniramine | The therapeutic efficacy of Dexbrompheniramine can be decreased when used in combination with Tacrine. |
| Dexchlorpheniramine maleate | The therapeutic efficacy of Dexchlorpheniramine maleate can be decreased when used in combination with Tacrine. |
| Dicyclomine | The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Tacrine. |
| Difenoxin | The therapeutic efficacy of Difenoxin can be decreased when used in combination with Tacrine. |
| Dimenhydrinate | The therapeutic efficacy of Dimenhydrinate can be decreased when used in combination with Tacrine. |
| Diphenhydramine | The therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Tacrine. |
| Diphenoxylate | The therapeutic efficacy of Diphenoxylate can be decreased when used in combination with Tacrine. |
| Dipyridamole | The therapeutic efficacy of Tacrine can be decreased when used in combination with Dipyridamole. |
| Disopyramide | The therapeutic efficacy of Disopyramide can be decreased when used in combination with Tacrine. |
| Doxepin | The therapeutic efficacy of Doxepin can be decreased when used in combination with Tacrine. |
| Doxylamine | The therapeutic efficacy of Doxylamine can be decreased when used in combination with Tacrine. |
| Droperidol | The therapeutic efficacy of Droperidol can be decreased when used in combination with Tacrine. |
| Esmolol | Tacrine may increase the bradycardic activities of Esmolol. |
| Fenoterol | The therapeutic efficacy of Fenoterol can be decreased when used in combination with Tacrine. |
| Fesoterodine | The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Tacrine. |
| Fexofenadine | The therapeutic efficacy of Fexofenadine can be decreased when used in combination with Tacrine. |
| Flavoxate | The therapeutic efficacy of Flavoxate can be decreased when used in combination with Tacrine. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Tacrine. |
| Flupentixol | The therapeutic efficacy of Flupentixol can be decreased when used in combination with Tacrine. |
| Fluphenazine | The therapeutic efficacy of Fluphenazine can be decreased when used in combination with Tacrine. |
| Fluticasone Propionate | The therapeutic efficacy of Fluticasone Propionate can be decreased when used in combination with Tacrine. |
| Glycopyrrolate | The therapeutic efficacy of Glycopyrrolate can be decreased when used in combination with Tacrine. |
| Guanidine | The risk or severity of adverse effects can be increased when Tacrine is combined with Guanidine. |
| Haloperidol | The therapeutic efficacy of Haloperidol can be decreased when used in combination with Tacrine. |
| Homatropine | The therapeutic efficacy of Homatropine can be decreased when used in combination with Tacrine. |
| Hydrocortisone | The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Tacrine. |
| Hydroxyzine | The therapeutic efficacy of Hydroxyzine can be decreased when used in combination with Tacrine. |
| Hyoscyamine | The therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Tacrine. |
| Iloperidone | Tacrine may increase the central neurotoxic activities of Iloperidone. |
| Imipramine | The therapeutic efficacy of Imipramine can be decreased when used in combination with Tacrine. |
| Ipratropium bromide | The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Tacrine. |
| Isocarboxazid | The therapeutic efficacy of Isocarboxazid can be decreased when used in combination with Tacrine. |
| Labetalol | Tacrine may increase the bradycardic activities of Labetalol. |
| Levocabastine | The therapeutic efficacy of Levocabastine can be decreased when used in combination with Tacrine. |
| Levocetirizine | The therapeutic efficacy of Levocetirizine can be decreased when used in combination with Tacrine. |
| Loratadine | The therapeutic efficacy of Loratadine can be decreased when used in combination with Tacrine. |
| Loxapine | The therapeutic efficacy of Loxapine can be decreased when used in combination with Tacrine. |
| Lurasidone | Tacrine may increase the central neurotoxic activities of Lurasidone. |
| Maprotiline | The therapeutic efficacy of Maprotiline can be decreased when used in combination with Tacrine. |
| Meclizine | The therapeutic efficacy of Meclizine can be decreased when used in combination with Tacrine. |
| Mepenzolate | The therapeutic efficacy of Mepenzolate can be decreased when used in combination with Tacrine. |
| Methacholine | The risk or severity of adverse effects can be increased when Tacrine is combined with Methacholine. |
| Methotrimeprazine | The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Tacrine. |
| Methscopolamine | The therapeutic efficacy of Methscopolamine can be decreased when used in combination with Tacrine. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Tacrine. |
| Metoprolol | Tacrine may increase the bradycardic activities of Metoprolol. |
| Moclobemide | The therapeutic efficacy of Moclobemide can be decreased when used in combination with Tacrine. |
| Nadolol | Tacrine may increase the bradycardic activities of Nadolol. |
| Nebivolol | Tacrine may increase the bradycardic activities of Nebivolol. |
| Nortriptyline | The therapeutic efficacy of Nortriptyline can be decreased when used in combination with Tacrine. |
| Olanzapine | The therapeutic efficacy of Olanzapine can be decreased when used in combination with Tacrine. |
| Olopatadine | The therapeutic efficacy of Olopatadine can be decreased when used in combination with Tacrine. |
| Orphenadrine | The therapeutic efficacy of Orphenadrine can be decreased when used in combination with Tacrine. |
| Oxybutynin | The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Tacrine. |
| Paliperidone | Tacrine may increase the central neurotoxic activities of Paliperidone. |
| Pancuronium | Tacrine may decrease the neuromuscular blocking activities of Pancuronium. |
| Penbutolol | Tacrine may increase the bradycardic activities of Penbutolol. |
| Perphenazine | The therapeutic efficacy of Perphenazine can be decreased when used in combination with Tacrine. |
| Phenelzine | The therapeutic efficacy of Phenelzine can be decreased when used in combination with Tacrine. |
| Pilocarpine | The risk or severity of adverse effects can be increased when Tacrine is combined with Pilocarpine. |
| Pimozide | The therapeutic efficacy of Pimozide can be decreased when used in combination with Tacrine. |
| Pindolol | Tacrine may increase the bradycardic activities of Pindolol. |
| Pizotifen | The therapeutic efficacy of Pizotifen can be decreased when used in combination with Tacrine. |
| Prednisolone | The risk or severity of adverse effects can be increased when Prednisolone is combined with Tacrine. |
| Prednisone | The risk or severity of adverse effects can be increased when Prednisone is combined with Tacrine. |
| Prochlorperazine | The therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Tacrine. |
| Procyclidine | The therapeutic efficacy of Procyclidine can be decreased when used in combination with Tacrine. |
| Promazine | The therapeutic efficacy of Promazine can be decreased when used in combination with Tacrine. |
| Promethazine | The therapeutic efficacy of Promethazine can be decreased when used in combination with Tacrine. |
| Propantheline | The therapeutic efficacy of Propantheline can be decreased when used in combination with Tacrine. |
| Propranolol | Tacrine may increase the bradycardic activities of Propranolol. |
| Protriptyline | The therapeutic efficacy of Protriptyline can be decreased when used in combination with Tacrine. |
| Quetiapine | The therapeutic efficacy of Quetiapine can be decreased when used in combination with Tacrine. |
| Repository corticotropin | The risk or severity of adverse effects can be increased when Repository corticotropin is combined with Tacrine. |
| Risperidone | The therapeutic efficacy of Risperidone can be decreased when used in combination with Tacrine. |
| Rocuronium | Tacrine may decrease the neuromuscular blocking activities of Rocuronium. |
| Scopolamine | The therapeutic efficacy of Scopolamine can be decreased when used in combination with Tacrine. |
| Scopolamine butylbromide | The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Tacrine. |
| Solifenacin | The therapeutic efficacy of Solifenacin can be decreased when used in combination with Tacrine. |
| Sotalol | Tacrine may increase the bradycardic activities of Sotalol. |
| Succinylcholine | The serum concentration of Succinylcholine can be increased when it is combined with Tacrine. |
| Thioridazine | The therapeutic efficacy of Thioridazine can be decreased when used in combination with Tacrine. |
| Thiothixene | The therapeutic efficacy of Thiothixene can be decreased when used in combination with Tacrine. |
| Timolol | Tacrine may increase the bradycardic activities of Timolol. |
| Tiotropium | The therapeutic efficacy of Tiotropium can be decreased when used in combination with Tacrine. |
| Tolterodine | The therapeutic efficacy of Tolterodine can be decreased when used in combination with Tacrine. |
| Tranylcypromine | The therapeutic efficacy of Tranylcypromine can be decreased when used in combination with Tacrine. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Triamcinolone is combined with Tacrine. |
| Trifluoperazine | The therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Tacrine. |
| Trihexyphenidyl | The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Tacrine. |
| Trimethobenzamide | The therapeutic efficacy of Trimethobenzamide can be decreased when used in combination with Tacrine. |
| Trimipramine | The therapeutic efficacy of Trimipramine can be decreased when used in combination with Tacrine. |
| Triprolidine | The therapeutic efficacy of Triprolidine can be decreased when used in combination with Tacrine. |
| Trospium | The therapeutic efficacy of Trospium can be decreased when used in combination with Tacrine. |
| Umeclidinium | The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Tacrine. |
| Vecuronium | Tacrine may decrease the neuromuscular blocking activities of Vecuronium. |
| Ziprasidone | Tacrine may increase the central neurotoxic activities of Ziprasidone. |
| Zuclopenthixol | The therapeutic efficacy of Zuclopenthixol can be decreased when used in combination with Tacrine. |
Food Interactions:
- Not Available
Taxonomy
Kingdom: Organic compounds
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
substituent:
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
- Aminopyridines and derivatives
- Aminoquinolines and derivatives
- Azacyclic compounds
- Benzenoids
- Heteroaromatic compounds
- Hydrocarbon derivatives
- Primary aromatic amines
substituent:
- Acridine
- Amine
- Aminopyridine
- Aminoquinoline
- Aromatic heteropolycyclic compound
- Azacycle
- Benzenoid
- Heteroaromatic compound
- Hydrocarbon derivative
- Organonitrogen compound
- Primary amine
- Primary aromatic amine
- Pyridine
References
Synthesis Reference: S. Shirley Yang, Wayne Boisvert, Nouman A. Muhammad, Jay Weiss, "Controlled release tacrine drug delivery systems and methods for preparing same." U.S. Patent US5576022, issued February, 1993.
General Reference: # Qizilbash N, Whitehead A, Higgins J, Wilcock G, Schneider L, Farlow M: Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration. JAMA. 1998 Nov 25;280(20):1777-82. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9842955 # Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20480924
External Links:
ATC Codes:
AHFS Codes:
MSDS: Download
General Reference: # Qizilbash N, Whitehead A, Higgins J, Wilcock G, Schneider L, Farlow M: Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration. JAMA. 1998 Nov 25;280(20):1777-82. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9842955 # Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20480924
External Links:
| Resource | Link |
|---|---|
| RxList | http://www.rxlist.com/cgi/generic2/tacrine.htm |
| Drugs.com | http://www.drugs.com/cdi/tacrine.html |
| Resource | Link |
|---|---|
| RxList | http://www.rxlist.com/cgi/generic2/tacrine.htm |
| Drugs.com | http://www.drugs.com/cdi/tacrine.html |
ATC Codes:
- Array
AHFS Codes:
- Not Available
MSDS: Download